Referring Doctors

Dear Doctor, Clinical research offers the possibility to many patients to participate in a protocol that provides them with an effective alternative for their pathologies.

In the event that you refer a patient to our center, we will maintain regular and fluid contact to keep you informed about your patient from the moment of evaluation. 

Studies recruiting patients

RECRUITING!

Metabolic acidosis in
kidney disease

TRICIDE STUDY

Phase 3 Study.

Evaluates the efficacy and safety of TRC-101 in the delay of Chronic Kidney Disease (CKD) with Metabolic Acidosis.

Research Product: TRC-101

TRC-101 is a hydrochloric acid (AC) binder that acts in the intestinal lumen, it is not absorbed and by binding AC it decreases its absorption and increases the concentration of bicarbonate in the blood, correcting metabolic acidosis. TRC-101 does not have the limitations that sodium bicarbonate does (standard treatment), for example: complication of HT, hydrosaline retention, etc; and it is expected that more patients with metabolic acidosis can be treated in order to decrease the progression of Chronic Kidney Disease, mortality, and increased muscle and bone deterioration typical of advanced stages of CKD.

To include patients in this study, they must have a creatinine clearance between 20 and 40 ml / min and bicarbonate 《at 20 meq / l. In case of not having measured the bicarbonate lately, we can carry out this practice in the center.

RECRUITING!

Heart
failure

DELIVER STUDY

Phase 3 Study

Evaluates the efficacy and safety of Dapagliflozin in the treatment of Heart Failure (HF) with a preserved left ventricular ejection fraction (》 40%).

Research Product: Dapagliflozin.

Dapagliflozin is already approved for the treatment of T2DM, it is currently being studied for patients with Heart Failure who have symptoms.
To include patients in this study, they must have symptoms of Heart Failure (at least functional class II dyspnea) and have a preserved left ventricular ejection fraction (measured by cardiac Doppler echo or MRI).

Currently, patients who have been hospitalized for HF in the last month are being incorporated.

RECRUITING!

Anemia and
Renal insufficiency

ASCEND STUDY

Phase 3 Study.

Evaluates the efficacy and safety of Daprodustat in the treatment of Anemia in patients with Chronic Kidney Disease.

Research Product: Daprodustat.

Daprodustat stimulates the production of Erythropoietin by the Kidney. Daprodustat is expected to be safer than the use of Erythropoietin. Fewer cardiovascular events are expected.

To include patients in this study, they must have anemia defined by Hemoglobin between 8 and 12 gr% and a creatinine clearance <60.
The study has a screening closing date for September 26, 2020.

RECRUITING!

Rheumatoid arthritis
resistant to treatments

CONTRAST STUDY

Phase 3 Study

The objective of this study is to determine the efficacy and safety of GSK3196165 (Otilimab), in combination with methotrexate (MTX) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to MTX. Otilimab (SC per week) will be compared to tofacitinib (5 mg twice daily), a Janus kinase inhibitor (JAK) that is approved for the treatment of adults with moderately to severely active RA.

Evaluates efficacy and safety of GSK3196165 (Otilimab) compared to placebo and t

Research Product: GSK3196165 (Otilimab)

Otilimab is a monoclonal antibody that specifically binds to human GM-CSF and prevents its interaction with its receptor. GM-CSF is a pro-inflammatory cytokine that favors synovial inflammation in RA since an increase in GM-CSF levels was observed in the synovial fluid of patients with RA and its receptor is expressed in synovial tissue. Elimination or neutralization of GM-CSF improves joint pain, function, and histological structure in patients with RA.

This study is aimed at patients with moderately to severely active RA, unresponsive to methotrexate.

RECRUITING!

Patients with
COPD and Eosinophilia

208657 STUDY

Phase 3 Study.

MEPOLIZUMAB as an additional treatment for patients with COPD characterized by frequent exacerbations and levels of EOSINOPHILS

Research Product: MEPOLIZUMAB.

Mepolizumab is a monoclonal antibody that inhibits the ability of IL-5. Monthly SC    

Inclusion criteria

  • >  40 years
  • Blood eosinophil count> 300 cells
  • COPD diagnosis> one year.
  • FEV greater than 20% and less than 80% 
  • At least 2 exacerbations in the last year that have required systemic corticosteroids or antibiotics (OR both) or a HOSPITALITY x exacerbation in the last year.
  • Triple therapy treatment. LABA / LAMA / ICS. 
  • Current or former smokers with a history of smoking ≥10 packs per year.

If you want to be contacted Please complete the form below

Open chat